


Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology.
2012;142(6):1293-1302.


Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich D, Mullen MP, et al. Liver fibrosis during an outbreak of acute...


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals. 15th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy. 2014.;


Khatri A, Trinh R, Zhao W. Drug-drug interactions of ombitasvir/paritaprevir/r plus dasabuvir with dolutegravir or abacavir plus lamivudine. 16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy. 2015.


Krishnan P, Pilot-Matias T, Schnell G, Tripathi R, Ng TI, Reisch T, et al. Pooled Resistance Analysis in HCV Genotype 1-6 Infected Patients Treated With Glecaprevir/Pibrentasvir in Phase 2 and 3 Clinical Trials [Epub ahead of print].
Antimicrobial Agents and Chemotherapy. 2018;


Lawitz EJ, Gane EJ, Pearlman B, Tam E, Ghesquiere W, Guyader D, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-86.


Martin TCS, Singh GJagjit, McClure M, Nelson M. HCV reinfection among HIV-positive men who have sex with men: A


Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews. 2014;(2).


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;


Reau N, Kwo PY, Rhee S. MAGELLAN-2: Safety and Efficacy of Glecaprevir/Pibrentasvir in Liver or Renal Transplant Adults with Chronic Hepatitis C Genotype 1-6 Infection. In EASL International Liver Meeting, April. 2017.


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.

Tice JA, Chahal HS, Ollendorf DA. Comparative clinical effectiveness and value of novel interferon-free combination therapy for hepatitis C genotype 1 summary of California technology assessment forum report. JAMA Internal Medicine. 2015;175(9):1559-1560.


U.S. Congressional Budget Office. Prescription drug pricing in the private sector. 2015.


